EPAS1 and renal cell carcinoma: For example, PT2385, as a selective inhibitor of HIF-2α, inhibits the transcriptional activity of HIF-2α by directly binding with HIF-2α protein and blocking its binding with HIF-1β (Arnaiz et al., 2021), but PT2385 is mainly used in the treatment of HIF-2α-related renal cell carcinoma (Courtney et al., 2018), and the therapeutic effect in other tumors is less studied.